Tag Archives: Europe

Compliance and Disclosure Risks on Anti-Competitive Promotional Spend: Is EuroLand Set to Follow the US?

By William Looney | Published: November 24, 2010
New Cegedim survey documents whether European industry is ready for the challenge. Making sense of the promotional spend and anti-corruption compliance burden is emerging as a key strategic issue for pharma — not just in the US but in the global market space as well, where regulatory safeguards are still porous. New survey research just published [...]
Posted in Global, Legal, Regulatory, compliance | Also tagged , , , , | 1 Comment

NICE News or Bad News?

By William Looney | Published: November 3, 2010
Far from losing its mojo, the UK’s National Institute for Health and Clinical Excellence (NICE) will simply be sharing the stage with a range of new players under NHS reform — none of whom look supportive of the R&D industry. The big issue for industry in the UK this week is handicapping the future of its [...]
Posted in Europe, Global, Regulatory | Also tagged , , , , , , , | Leave a comment

And What Exactly is a Stakeholder?

By Julian Upton | Published: August 19, 2010
Pharma’s uncritical use of the word ‘stakeholder’ has increased to the point where it can refer to almost anyone connected to the industry. But this can have serious consequences, warns Reflector. Like it or not (and frankly, I don’t), stakeholders are here to stay in European pharmaceutical affairs. Don’t get me wrong. I’ve no objection to [...]
Posted in Europe, Global, Guest Blog, Regulatory | Also tagged , , , , , , , | 1 Comment

Europe’s Fiscal Crisis: Can Big Pharma Emerge Unscathed?

By William Looney | Published: June 2, 2010
Europe’s current fiscal crisis, symbolized by the meltdown in Greece, is seen by big pharma as a temporary situation to be taken in stride—after all, the EU southern and eastern tier, with its chronically shaky finances and per capita incomes as low as a third of the EU norm, has historically been a marginal player [...]
Posted in Europe | Also tagged , , , , , | 2 Comments

Nothing is Rotten in the State of Denmark

By Julian Upton | Published: March 2, 2010
Guest blog by Reflector, Pharm Exec Europe’s Brussels correspondent. Denmark is still on the fringes of some European Union policies. Notably, it has not yet embraced the euro as a currency, and it keeps its distance from the common defence policy. But in one respect, its pharmaceutical industry has just shown that it is well abreast [...]
Posted in Europe, Global, Guest Blog, Regulatory | Also tagged , , , , , , | Leave a comment